---
title: "活躍股票：Satellos Bioscience Inc"
description: "東部時間上午 10:21 - Satellos Bioscience Inc.：今天宣佈，第一位參與者已在 BASECAMP 中接受治療，該研究是一項為期三個月的隨機、雙盲、安慰劑對照的概念驗證二期兒童研究，旨在評估 SAT-3247 對杜氏肌營養不良症的療效。Satellos Bioscience Inc.的股票 T.MSCL 上漲 0.43 美元，報 16.20 美元"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275777320.md"
published_at: "2026-02-12T15:22:17.000Z"
---

# 活躍股票：Satellos Bioscience Inc

> 東部時間上午 10:21 - Satellos Bioscience Inc.：今天宣佈，第一位參與者已在 BASECAMP 中接受治療，該研究是一項為期三個月的隨機、雙盲、安慰劑對照的概念驗證二期兒童研究，旨在評估 SAT-3247 對杜氏肌營養不良症的療效。Satellos Bioscience Inc.的股票 T.MSCL 上漲 0.43 美元，報 16.20 美元

**美國東部時間上午 10:21 - Satellos Bioscience Inc. :** 今天宣佈，第一位參與者已在 BASECAMP 中接受治療，該研究是針對 Duchenne 肌營養不良症的為期三個月的隨機、雙盲、安慰劑對照的概念驗證第二階段兒童研究。Satellos Bioscience Inc. 的股票 T.MSCL 目前上漲 **0.43 美元**，報 16.20 美元。

### Related Stocks

- [IBB.US - 納斯達克生物科技指數 ETF - iShares Nasdaq](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [SBIO.US - 醫藥突破 ETF - ALPS](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [ASMB.US - Assembly生物科技](https://longbridge.com/zh-HK/quote/ASMB.US.md)
- [LABD.US - 標普生物技術 3 倍做空 - Direxion](https://longbridge.com/zh-HK/quote/LABD.US.md)
- [TBIO.US - Telesis Bio](https://longbridge.com/zh-HK/quote/TBIO.US.md)
- [MSLE.US - Satellos Bioscience](https://longbridge.com/zh-HK/quote/MSLE.US.md)
- [PBE.US - 動態生物技術與基因組 ETF - Invesco](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [BIB.US - 2 倍做多納斯達克生物技術 ETF - ProShares](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [FBT.US - 紐交所高增長板生物技術指數 ETF - First Trust](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [BBH.US - 生物科技 ETF - VanEck Vectors](https://longbridge.com/zh-HK/quote/BBH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Artisan Partners Limited Partnership Grows Stake in Twist Bioscience Corporation $TWST | Artisan Partners Limited Partnership increased its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 26.7% in Q3, o | [Link](https://longbridge.com/zh-HK/news/277163890.md) |
| ImmunityBio Supersedes Expectations With Fivefold Revenue Increase | ImmunityBio Inc. (NASDAQ:IBRX) reported a fivefold revenue increase, driven by a 750% surge in Anktiva sales, reaching $ | [Link](https://longbridge.com/zh-HK/news/276923608.md) |
| Exploring Belite Bio's Earnings Expectations | Belite Bio (NASDAQ:BLTE) will report its quarterly earnings on March 2, 2026, with analysts estimating an EPS of $-0.55. | [Link](https://longbridge.com/zh-HK/news/277224746.md) |
| Delcath Q4 revenue rises 37%, beats estimates | Delcath Systems reported a 37% increase in Q4 revenue, surpassing analyst expectations with $20.73 million. Despite a ne | [Link](https://longbridge.com/zh-HK/news/277046688.md) |
| Uncovering Potential: Akebia Therapeutics's Earnings Preview | Akebia Therapeutics (NASDAQ:AKBA) is set to release its quarterly earnings report on February 26, 2026, with analysts pr | [Link](https://longbridge.com/zh-HK/news/276923521.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。